A total of 189 eyes of 160 patients with exudative AMD treated with intravitreal anti–vascular endothelial growth factor therapy (anti-VEGF) injections (ranibizumab 0.3 mg/0.05 mL, aflibercept 2 mg/0.05 mL, bevacizumab 1.25 mg/0.05 mL) were included in the study. This evidence concerns the gene VEGFA and age-related macular degeneration.